Delafloxacin is a novel anionic fluoroquinolone with enhanced activity in acidic environments typical of infected tissue and biofilms, used for acute bacterial skin and skin-structure infections and community-acquired pneumonia. Simson Pharma's Delafloxacin reference standard and impurities support stability-indicating method development for this next-generation fluoroquinolone.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Delafloxacin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.